A Longitudinal Cohort Study to Assess Effectiveness and B-memory Response to the Quadrivalent HPV Vaccine 9 Years Post-vaccination Among HIV-Infected Boys and Girls Ages 9-14 Years in Kenya
Latest Information Update: 30 Nov 2023
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 23 Nov 2023 Status changed from active, no longer recruiting to completed.
- 21 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2022 New trial record